• Consensus Rating: Buy
  • Consensus Price Target: $29.80
  • Forecasted Upside: 66.57%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$17.89
▲ +0.39 (2.23%)

This chart shows the closing price for HROW by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Harrow Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HROW and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HROW

Analyst Price Target is $29.80
▲ +66.57% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Harrow in the last 3 months. The average price target is $29.80, with a high forecast of $34.40 and a low forecast of $26.00. The average price target represents a 66.57% upside from the last price of $17.89.

This chart shows the closing price for HROW for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 investment analysts is to buy stock in Harrow. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/2/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/29/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/27/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/25/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/15/2024Craig HallumBoost TargetBuy ➝ Buy$24.00 ➝ $26.00Low
5/15/2024B. RileyReiterated RatingBuy ➝ Buy$26.00 ➝ $29.00Low
4/11/2024Craig HallumInitiated CoverageBuy$24.00Low
3/22/2024B. RileyLower TargetBuy ➝ Buy$30.00 ➝ $26.00Low
8/10/2023LADENBURG THALM/SH SHBoost Target$33.70 ➝ $34.40Low
7/20/2023B. RileyBoost TargetBuy$42.00 ➝ $45.00Low
5/12/2023LADENBURG THALM/SH SHBoost Target$27.20 ➝ $32.40Low
5/4/2023B. RileyReiterated RatingBuyLow
4/17/2023Lake Street CapitalBoost TargetBuy$24.00 ➝ $37.00Low
1/24/2023Lake Street CapitalBoost Target$17.00 ➝ $24.00Low
1/5/2023B. RileyBoost Target$17.00 ➝ $22.00Low
9/8/2022B. RileyInitiated CoverageBuy$17.00Low
5/20/2022B. RileyBoost TargetBuy$17.00 ➝ $20.00High
10/14/2021B. RileyInitiated CoverageBuy$16.00Medium
9/23/2021AegisInitiated CoverageBuy$15.00High
7/2/2021LADENBURG THALM/SH SHInitiated CoverageBuy$14.25Medium
5/12/2021B. RileyBoost TargetBuy$14.00 ➝ $15.00High
1/4/2021B. RileyBoost TargetOutperform ➝ Buy$12.00 ➝ $14.00N/A
4/7/2020B. RileyLower TargetBuy$12.00 ➝ $10.00Low
3/16/2020B. RileyLower TargetBuy$12.75 ➝ $12.00High
8/16/2019Lake Street CapitalSet TargetBuy$15.00Low
(Data available from 5/25/2019 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/28/2023
  • 1 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
11/27/2023
  • 3 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/27/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/26/2024
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2024
  • 11 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/26/2024
  • 8 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 9 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
5/25/2024

Current Sentiment

  • 9 very positive mentions
  • 21 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Harrow logo
Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.
Read More

Today's Range

Now: $17.89
Low: $17.07
High: $17.95

50 Day Range

MA: $12.52
Low: $10.00
High: $17.89

52 Week Range

Now: $17.89
Low: $7.60
High: $24.19

Volume

249,439 shs

Average Volume

572,453 shs

Market Capitalization

$632.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Harrow?

The following Wall Street analysts have issued reports on Harrow in the last twelve months: B. Riley, Craig Hallum, LADENBURG THALM/SH SH, and TheStreet.
View the latest analyst ratings for HROW.

What is the current price target for Harrow?

3 Wall Street analysts have set twelve-month price targets for Harrow in the last year. Their average twelve-month price target is $29.80, suggesting a possible upside of 66.6%. LADENBURG THALM/SH SH has the highest price target set, predicting HROW will reach $34.40 in the next twelve months. Craig Hallum has the lowest price target set, forecasting a price of $26.00 for Harrow in the next year.
View the latest price targets for HROW.

What is the current consensus analyst rating for Harrow?

Harrow currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HROW will outperform the market and that investors should add to their positions of Harrow.
View the latest ratings for HROW.

What other companies compete with Harrow?

How do I contact Harrow's investor relations team?

Harrow's physical mailing address is 102 Woodmont Blvd. Suite 610, Nashville TN, 37205. The company's listed phone number is (615) 733-4730 and its investor relations email address is [email protected]. The official website for Harrow is www.harrowinc.com. Learn More about contacing Harrow investor relations.